Leading eye care hospital chain built around Tamil Nadu, offering cataract, retina and refractive surgery plus opticals.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 51 | 50 | 73 | 109 | 152 | 205 | 310 | 341 |
| Borrowings | 60 | 68 | 193 | 232 | 268 | 333 | 335 | 326 |
| Other Liabilities | 24 | 33 | 42 | 44 | 71 | 71 | 79 | 94 |
| Total Liabilities | 141 | 155 | 314 | 390 | 496 | 613 | 729 | 766 |
| AssetsFixed Assets | 94 | 96 | 214 | 260 | 316 | 393 | 409 | 403 |
| CWIP | 0 | 0 | 26 | 62 | 97 | 128 | 157 | 197 |
| Investments | 0 | 0 | 0 | 0 | 0 | 13 | 85 | 89 |
| Other Assets | 47 | 60 | 73 | 67 | 83 | 80 | 79 | 78 |
| Total Assets | 141 | 155 | 314 | 390 | 496 | 613 | 729 | 766 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 25 | 39 | 34 | 57 | 70 | 90 | 94 | 145 |
| Cash from Investing | -25 | -17 | -11 | -46 | -71 | -70 | -133 | -174 |
| Cash from Financing | 2 | -20 | -8 | -4 | 0 | -14 | 17 | 25 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 0 | 22 | 23 | 10 | -1 | 19 | -8 | 47 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (32.2×) and current (34.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 23.1% growth and a 32× exit, ₹5003 only delivers your return if you pay ₹6,031. The price is currently baking in 19% growth.
EPS grows 23.1%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 23.1% | 179.80 |
| FY28 | 23.1% | 221.33 |
| FY29 | 23.1% | 272.46 |
| FY30 | 23.1% | 335.40 |
| FY31 | 23.1% | 412.88 |
| FY32 | 14.6% ·fade | 472.95 |
| FY33 | 6.0% ·fade | 501.33 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.